Lemaitre Vascular (LMAT) reported $250M in revenue for fiscal 2025, +13.5% year on year. That ranks #2574 by revenue among 2853 SEC filers and #265 in Healthcare. Net income was $57.7M, a net margin of 23.1%. Revenue has grown 12.1% a year on average since 2016 ($89.2M then). The fiscal 2025 balance sheet shows $616M in total assets and $28.2M in cash.
Key figures
| Key figures | FY2025 | YoY | Source |
|---|---|---|---|
| RevenueRevenueFromContractWithCustomerExcludingAssessedTax | $250M | +13.5% | FY20252025-12-31 |
| Gross profitGrossProfit | $179M | +18.3% | FY20252025-12-31 |
| Operating incomeOperatingIncomeLoss | $67.9M | +30.0% | FY20252025-12-31 |
| Net incomeNetIncomeLoss | $57.7M | +31.1% | FY20252025-12-31 |
| Operating cash flowNetCashProvidedByUsedInOperatingActivities | $81.3M | +84.1% | FY20252025-12-31 |
| Capital expenditurePaymentsToAcquireProductiveAssets | $6.8M | −2.6% | FY20252025-12-31 |
| Total assetsAssets | $616M | +11.6% | FY20252025-12-31 |
| Shareholders' equityStockholdersEquity | $394M | +16.7% | FY20252025-12-31 |
| CashCashAndCashEquivalentsAtCarryingValue | $28.2M | +10.3% | FY20252025-12-31 |
| Long-term debt | Not reported | — |
Revenue is total net sales for the fiscal year, taken from each company's own annual filing.
Reported since the last full year
Three-month figures this company has filed since FY2025. A quarter is not comparable with a full year, and these figures are used nowhere else on the site: not in any ranking, not in comparisons, not in the download.
| Quarter | Revenue | Net income | Source |
|---|---|---|---|
| Q1 20262026-03-31 | $66.6M | $15.7M | Open → |
| Q2 20262026-06-30 | $70.4M | $17.1M | Open → |
Only periods that end on a calendar quarter appear here. A company whose fiscal year ends in June files on a different calendar, so it has no row.
Profile
- Legal name
- Lemaitre Vascular Inc
- Ticker
- LMAT
- Exchange
- Nasdaq
- SIC classification
- Surgical & Medical Instruments & Apparatus (3841)
- Fiscal year end
- 12-31
- CIK
- 0001158895
Filings
- 10-QAug 5, 2026Open filing →
- 10-QMay 6, 2026Open filing →
- 10-KFeb 26, 2026Open filing →
Similar in size, same sector
| Company | Revenue | Net income |
|---|---|---|
| ArvinasARVN | $263M | −$81.0M |
| Omada HealthOMDA | $260M | −$12.8M |
| SchrodingerSDGR | $256M | −$103M |
| Lemaitre VascularLMAT | $250M | $57.7M |
| Arcus BiosciencesRCUS | $247M | −$353M |
| Keros TherapeuticsKROS | $244M | $87.0M |
| Staar SurgicalSTAA | $239M | −$80.4M |
Cite this page
Ready-made references for the figures on this page, as published on September 25, 2026.
Wikipedia
{{cite web |title=Lemaitre Vascular — Key figures |url=https://companiesranked.com/en/company/lemaitre-vascular |website=CompaniesRanked |date=2026-09-25 |language=en}}APA 7
CompaniesRanked. (September 25, 2026). Lemaitre Vascular — Key figures. CompaniesRanked. https://companiesranked.com/en/company/lemaitre-vascularBibTeX
@misc{companiesranked-en-company-lemaitre-vascular-2026,
author = {{CompaniesRanked}},
title = {{Lemaitre Vascular — Key figures}},
year = {2026},
howpublished = {\url{https://companiesranked.com/en/company/lemaitre-vascular}},
note = {Compiled from SEC EDGAR XBRL filings; data as of 2026-09-25},
urldate = {2026-09-25}
}The filing itself
The numbers above are read from this document: 10-K · 0001193125-26-073360 · February 26, 2026
{{cite web |title=Lemaitre Vascular — Key figures — 10-K (0001193125-26-073360) |url=https://www.sec.gov/Archives/edgar/data/1158895/000119312526073360/ck0001158895-20251231.htm |website=SEC EDGAR |publisher=U.S. Securities and Exchange Commission |date=2026-02-26}}The figures are rebuilt with every data refresh, so the reference carries the publication date. Add your own access date if your style requires one.